New hope for kids with tough cancers: targeted drug trial now open
Disease control
Recruiting now
This study tests a drug called repotrectinib in children and young adults (up to age 25) whose advanced cancers have specific genetic changes (ALK, ROS1, or NTRK1-3). The goal is to find the best dose and see if the drug shrinks tumors. Participants must have tried other treatmen…
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC